People in the News

Aug 16, 2018

Jeffrey Henderson

Becton Dickinson has elected Jeffrey Henderson to its board of directors. Henderson is the non-executive chairman of the board of Qualcomm, serves on the boards of FibroGen and Halozyme Therapeutics, and is an advisory director to Berkshire Partners. He previously served as CFO of Cardinal Health for nearly 10 years and has also held positions at Eli Lilly and General Motors.

Aug 09, 2018

Albert Parker

OncoCyte has appointed Albert Parker as its chief operating officer. According to the company, Parker is an attorney and executive with more than 25 years of pharmaceutical, biotech, and healthcare experience. Prior to joining OncoCyte, Parker served as the managing shareholder of GC Legal Advisors, where he represented and advised public and privately held companies, primarily in the life sciences industry. Among other prior roles, Parker has also served as executive VP, general counsel, and corporate secretary at Sunovion Pharmaceuticals, senior VP and chief counsel for Wyeth Pharmaceuticals, and partner at Schnader Harrison Segal & Lewis.

Aug 09, 2018

Kathleen LaPorte

Precipio has appointed Kathleen LaPorte to its board as an independent member. She will replace Michael Allen Luther, who first served on the board of Transgenomic starting in 2014 and remained on it after that firm merged with Precipio.  

LaPorte was a general partner with Sprout Group from 1993 to 2004 and was a founder of New Leaf Venture Partners. She is also a cofounder of Health Tech Capital and was CEO of immuno-oncology diagnostic company Nodality. 

Aug 09, 2018

Hal Barron, Hans Bishop

Grail has appointed Hal Barron and Hans Bishop to its board. Barron is the CSO and president of R&D at GlaxoSmithKline. Prior to that, he served as president of R&D at Calico. He has also held management positions at Roche Pharmaceuticals and Genentech and is associate adjunct professor of epidemiology and biostatistics at the University of California, San Francisco. 

Bishop founded Juno Therapeutics in 2013 and was the firm's president and CEO until this past March when it was acquired by Celgene. He previously served as executive-in-residence at Warburg Pincus and is currently on the boards of Agilent Technologies and Celgene.

Aug 08, 2018

Mary Lake Polana

Chembio Diagnostics appointed Mary Lake Polana, a professor of clinical obstetrics, gynecology, and reproductive sciences at Yale University School of Medicine, to its board of directors. 

Polan focuses on reproductive health for women. She is a women's health researcher, and her work on ovarian function, reproductive endocrinology, and infertility has been published and cited throughout the scientific community. Polan has experience in leadership roles at several medical schools, and prior to Yale, she served as an adjunct professor in the obstetrics and gynecology department at Columbia University School of Medicine. Previously, Polan spent 15 years as the chair of the department of obstetrics and gynecology at Stanford University School of Medicine.

Aug 07, 2018

David Macdonald

First Light Biosciences has appointed David Macdonald its president, CEO, and board member. He was most recently CEO of Agendia, and before that was a division president, COO and vice president at Quest Diagnostics. 

Aug 06, 2018

Mitchell Nelles

CareDx Chief Operating Officer Mitchell Nelles told the company on July 31 that he intends to retire, effective Sept. 28, according to a document filed with the US Securities Exchange Commission. Nelles joined CareDx in 2007, when it was called XDx, as VP of R&D. Prior to that, Nelles served as VP of North American R&D at BioMérieux.

Aug 02, 2018

Eric Stawiski

Eric Stawiski has been appointed vice president of bioinformatics at MedGenome. He is tasked with scaling up the company's bioinformatics services and building new products and IP. He was previously at Genentech where he was a group leader for a team focused on analyzing RNA-seq, exome, and copy number data to identify potential driver genes and drug targets in cancers, as well as evaluating new sequencing technologies. 

Jul 31, 2018

Didier Hirsch, Robert McMahon, Karleen Oberton

Agilent Technologies said its senior VP and CFO Didier Hirsch will retire, effective Oct 31. The company has appointed Robert McMahon, currently CFO of Hologic, as his successor. McMahon will join Agilent on Aug. 3 as senior VP and will become CFO on Sept. 1 when Hirsch steps down from that post. Hirsch will continue as an active member of the executive staff until his retirement date at the end of the fiscal year and will work with McMahon to ensure a smooth transition.

Hirsch has served as Agilent's CFO since 2010. Before that, he had oversight of the corporate controllership and tax functions. He joined Agilent in 1999 as VP of treasury and investor relations. He also held various international finance positions at HP from 1989 until joining Agilent.
McMahon has served as Hologic's CFO since 2014. Prior to that, he spent 20 years with Johnson & Johnson, most recently as worldwide VP of finance and business development for Ortho Clinical Diagnostics. He also held a variety of financial leadership positions within Johnson & Johnson after joining the company in 1993.

Separately, Hologic said it would promote its current Chief Accounting Officer Karleen Oberton to replace McMahon as CFO. She joined Hologic in 2006 as corporate controller and was promoted to her current position in 2015. Prior to that, Oberton served as senior corporate controller for Immunogen, and as a senior audit manager for both Ernst Young and Arthur Andersen.

Jul 31, 2018

Rishi Kacker, Alexander Ford, Eric Evans, Lloyd Sanders

As part of Myriad Genetics' integration with recently acquired firm Counsyl, the company announced a number of personnel changes. Rishi Kacker, formerly Counsyl's senior VP of technology, will become Myriad's new chief technology officer. Alexander Ford, previously president of Myriad Genetic Laboratories, will be president of the company's women's health business unit, while Eric Evans, Counsyl's chief scientific officer, will now serve as the chief scientific officer of the women's health unit. Lastly, Lloyd Sanders, previously general manager of the oncology segment, will be president of Myriad's oncology business unit.

Jul 31, 2018

Mark McDonough

Mark McDonough has been named chief business officer at diagnostics and bioinformatics firm Phosphorus. McDonough was previously president and CEO of CombiMatrix, now part of Invitae. He also held senior executive positions at Pathwork Dx and Laboratory Corporation of America. Phosphorus offers genetics testing in fertility, cardiology, lipidology, and other indications. It also offers the Elements software platform for labs to deploy the company's genetic tests on-premise as a local solution.

Jul 31, 2018

Roy Baynes

Natera has appointed Roy Baynes to its board of directors. Baynes is chief medical officer at Merck and senior vice president and head of global clinical development at Merck Research Laboratories. He has also held several roles at Gilead Sciences and Amgen and is a member of the American Society of Hematology, American Society of Clinical Oncology, and American Association for Cancer Research. Prior to joining industry, Baynes was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute.

Jul 31, 2018

Mohsin Meghji

Mohsin Meghji has joined the board of Bioaffinity Technologies. Managing partner at merchant banking and advisory firm M-III Partners, Meghji replaces Barry Frankel. He founded M-III in late 2014. Prior to that, he was executive vice president and head of strategy at Springleaf Holdings and CEO of its captive insurance companies. Meghji is chairman of the board at Infrastructure & Energy Alternatives.

Jul 24, 2018

Ted Hull

Bako Diagnostics has appointed Ted Hull its CEO, effective Aug. 1. He succeeds Larry McCarthy who served as interim CEO and is Bako's chairman. Hull has more than 25 years of industry experience including 15 years at Genova Diagnostics where he was CFO then chairman and CEO. He was most recently managing partner of Ramble Ventures. 

Bako provides diagnostic and therapeutic services to the podiatric medical community with a focus on pathology for the lower extremity. Its testing menu includes epidermal nerve fiber density analysis, mass spectrometry for the identification of bacteria from culture specimens, and molecular genetics for detecting microorganisms and as a diagnostic aid in certain pathologic diagnoses.

Jul 24, 2018

George Church, David Walt, Kevin Chen

Molecular diagnostics firm NuProbe Global has formed a scientific advisory board and appointed a new member to its board of directors. The firm has named George Church and David Walt as members of the scientific board. Church and Walt are currently professors of genetics and pathology, respectively, at Harvard Medical School. The firm has also appointed Kevin Chen, founding partner at Biotrack Capital, as a member of the board of directors. Chen has previously led investment in healthcare companies including Beijing Genomics Institute (BGI), Betta Pharma, and Yuwell Medical. 

Jul 23, 2018

Jeanne Mell

Jeanne Mell has been appointed vice president of corporate communications for OraSure Technologies, effective Aug. 13. She was most recently VP of marketing communications at the University City Science Center in Philadelphia. Prior to that, Mell was senior VP of communications for the Delaware State Chamber of Commerce.

Jul 19, 2018

Christine Rousseau

Chembio Diagnostics has appointed Christine Rousseau to the newly created position of vice president of corporate development, effective immediately. She will focus on the company's point-of-care infectious disease diagnostics strategy and execution, including HIV self-testing, and fever and tropical diseases, as well as collaborations leveraging Chembio's DPP technology platform and expertise. Rousseau was previously at the Bill & Melinda Gates Foundation, most recently as senior program officer of Global Health, Integrated Technology Solutions. Prior to that, she was a research scientist and faculty member at the University of Washington.

Jul 19, 2018

Owlstone Medical Expanded Scientific Advisory Board

Owlstone Medical has expanded its scientific advisory board with the appointment of five experts. They are Bruce Ponder, emeritus professor of oncology at the University of Cambridge, UK; Patrick Bossuyt, professor of clinical epidemiology at the University of Amsterdam; Christian Frezza, a Medical Research Council program leader at the MRC Cancer Unit, University of Cambridge; Chris Mayhew, director of the Institute for Breath Research at the University of Innsbruck; Anil Modak, former associate director of medical products research and development at Cambridge Isotope Laboratories; and Alan Boobis, professor of toxicology at Imperial College London.

Jul 17, 2018

Laurence Klotz

MiR Scientific (formerly miR Diagnostics) has appointed Laurence Klotz as chief medical officer. Klotz currently serves as chairman of the World Urologic Oncology Federation. He has also been a member of the Institute of Medical Science and a graduate faculty member at the University of Toronto since 2005, as well as a professor of surgery at the University of Toronto since 2000.

Jul 17, 2018

Matthew Walls

Former Genedrive CEO Matthew Walls has been appointed chairman of UK women's healthcare firm Concepta, effective immediately. The former chairman, Adam Reynolds, will move into a non-executive role. Walls was also chief executive of patient behavioral change company Atlantis Healthcare Group and chairman of The Fertility Partnership in the UK. 

Concepta also appointed Peter Dines as a non-executive director, effective immediatley. Dines is the COO and head of life sciences and biosciences at Marcia Technologies, Concepta's major shareholder. Mark Wyatt is stepping down as a non-executive director to focus on other business interests, Concepta said. The company was founded in 2013 with a focus on helping women with fertility issues and has developed a proprietary platform and fertility product for home self-testing or for the doctor's office. 

Jul 13, 2018

Leena Das-Young

Guardant Health has appointed Leena Das-Young to serve as general manager of its LUNAR program. In her new role, Das-Young will oversee all work applying Guardant Health's technology and database of more than 70,000 clinical Guardant360 assay results, toward new applications in early-stage cancer, such as residual detection, recurrence monitoring, and early detection.

Prior to joining Guardant, Das-Young was vice president and head of the late phase strategy development group at Pfizer's oncology group, where she was responsible for a portfolio of oncology programs including Ibrance, Xalkori, Besponsa, Sutent, lorlatinib, and others. Prior to her roles in product development, she served in various commercial roles responsible for several successful launches at both Pfizer and Bayer.  She holds BS and Doctor of Pharmacy degrees from Purdue University.

Jul 13, 2018

Jinjie Hu

Laboratory for Advanced Medicine announced today that it has appointed Jinjie Hu as the firm's Chief Regulatory Officer. Hu currently serves as President and principal consultant at Axteria BioMed Consulting, and as senior consultant for Biologics Consulting Group. Hu has also served as World Health Organization advisor for its diagnostic pre-qualification program, as well as the International Network Committee chair of the FDA alumni association. 

Jul 12, 2018

Johnson Chiang, Rixun Fang

Johnson Chiang has been appointed chief technology officer and Rixun Fang director of assay development at Alveo Technologies.

Chiang was previously head of systems integration and molecular biology at Foundation Medicine. He also held senior management positions at Life Technologies and at Thermo Fisher Scientific. Prior to that, he led molecular diagnostic product development projects at Applied MEMS, Applied Biosystems, and Cepheid.

Fang previously led several molecular biology research and IVD development projects at Applied Biosystems, Life Technologies, and Thermo Fisher Scientific.

Jul 12, 2018

Robert Mittelstaedt Jr., Adam Schechter

Laboratory Corporation of America announced that Robert Mittelstaedt, Jr., lead independent director, will retire from the LabCorp board of directors at the conclusion of his current term on May 9, 2019. Adam Schecter has been elected to serve as lead independent director effective Jan. 2, 2019, so that he and Mittelstaedt can work together on a smooth transition.

Mittelstaedt will retire from the board pursuant to the company's mandatory retirement policy, which provides that directors are not eligible for re-election at regularly scheduled annual shareholder meetings after the age of 75. Mittelstaedt became a director of LabCorp in 1996 and shared board executive sessions beginning in 2006. He has served as lead independent director since 2009. He has also served on various board committees including serving as chair of the nominating and corporate governance committee, chair of the compensation committee and member of the audit committee.

Jul 12, 2018

Freenome Impact Advisory Board

Freenome has announced the creation of what it calls its Impact Advisory Board, a group tasked with helping the company optimize strategies, including those that will guide its first commercial launch of a blood-based, artificial intelligence-derived genomic test for the early detection of colorectal cancer.

The new board includes NDA Partners' Alberto Gutierrez, a former 25-year veteran of the US Food and Drug Administration, who will be tasked with guiding regulatory strategy. Joining Gutierrez are two experts on payor strategy: Louis Jacques, chief clinical officer of ADVI Health and former head of the Centers for Medicare and Medicaid Services' Coverage and Analysis Group; and Sherie Smalley, senior medical director of medical policy at UPMC Health Plan.

It also includes clinical development advisors with expertise in gastroenterology, including Douglas Robertson from the US Multi-Society Task Force of Colorectal Cancer.

Pages